12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Gevokizumab: Completed Phase II enrollment

Xoma completed enrollment of about 90 patients in a placebo-controlled Phase II trial evaluating once-monthly 60 mg subcutaneous gevokizumab. Servier has worldwide rights to develop and commercialize gevokizumab for all indications, except in the U.S. and...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >